Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.03 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.4 million .

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.